Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Positive response to galcanezumab following treatment failure to onabotulinumtoxinA in patients with migraine: post hoc analyses of three randomized double‐blind studies
Jessica Ailani, Eric Pearlman, Q. Zhang, et al.
European Journal of Neurology (2019) Vol. 27, Iss. 3, pp. 542-549
Open Access | Times Cited: 22

Showing 22 citing articles:

Migraine
Michel D. Ferrari, Peter J. Goadsby, Rami Burstein, et al.
Nature Reviews Disease Primers (2022) Vol. 8, Iss. 1
Closed Access | Times Cited: 303
CGRP-targeted medication in chronic migraine - systematic review
Renato Oliveira, Raquel Gil‐Gouveia, Francesca Puledda
The Journal of Headache and Pain (2024) Vol. 25, Iss. 1
Open Access | Times Cited: 19
Erenumab in Chronic Migraine Patients Who Previously Failed Five First-Line Oral Prophylactics and OnabotulinumtoxinA: A Dual-Center Retrospective Observational Study
Bianca Raffaelli, Rea Kalantzis, Jasper Mecklenburg, et al.
Frontiers in Neurology (2020) Vol. 11
Open Access | Times Cited: 79
Monoclonal antibodies blocking CGRP transmission: An update on their added value in migraine prevention
Jean Schoenen, Maïté Manise, Romain Nonis, et al.
Revue Neurologique (2020) Vol. 176, Iss. 10, pp. 788-803
Open Access | Times Cited: 51
How to integrate monoclonal antibodies targeting the calcitonin gene-related peptide or its receptor in daily clinical practice
Cindy Tiseo, Raffaele Ornello, Francesca Pistoia, et al.
The Journal of Headache and Pain (2019) Vol. 20, Iss. 1
Open Access | Times Cited: 51
Efficacy and safety of monoclonal antibody against calcitonin gene-related peptide or its receptor for migraine patients with prior preventive treatment failure: a network meta-analysis
Xing Wang, Dingke Wen, Qiang He, et al.
The Journal of Headache and Pain (2022) Vol. 23, Iss. 1
Open Access | Times Cited: 23
Partial and nonresponders to onabotulinumtoxinA can benefit from anti‐CGRP monoclonal antibodies preventive treatment: A real‐world evidence study
Alicia Alpuente, Victor J Gallardo, Edoardo Caronna, et al.
European Journal of Neurology (2021) Vol. 28, Iss. 7, pp. 2378-2382
Closed Access | Times Cited: 26
Calcitonin-gene-related peptide pathway mAbs and migraine prevention
Koen Paemeleire, Antoinette MaassenVanDenBrink
Current Opinion in Neurology (2018) Vol. 31, Iss. 3, pp. 274-280
Closed Access | Times Cited: 25
OnabotulinumtoxinA: Discussion of the evidence for effectiveness of OnabotulinumA and its place in chronic migraine treatment
Vicente González‐Quintanilla, Stefan Evers, Julio Pascual
Handbook of clinical neurology (2024), pp. 87-106
Closed Access | Times Cited: 2
Comparative effectiveness and tolerability of calcitonin gene‐related peptide (CGRP) monoclonal antibodies and onabotulinumtoxinA in chronic migraine: A multicenter, real‐world study in Taiwan
Yen‐Feng Wang, Fu‐Chi Yang, Lu‐An Chen, et al.
European Journal of Neurology (2024) Vol. 31, Iss. 9
Open Access | Times Cited: 2
Efficacy and safety of galcanezumab for preventive treatment of migraine: a systematic review and meta-analysis
Xiuyuan Zhao, Xiaolin Xu, Qingyun Li
Journal of Neurology (2020) Vol. 268, Iss. 7, pp. 2364-2376
Open Access | Times Cited: 14
CGRP Targeting Therapy for Chronic Migraine—Evidence from Clinical Trials and Real-world Studies
Yen‐Feng Wang, Shuu‐Jiun Wang
Current Pain and Headache Reports (2022) Vol. 26, Iss. 7, pp. 543-554
Closed Access | Times Cited: 8
Efficacy of migraine prophylaxis treatments for treatment-naïve patients and those with prior treatment failure: a protocol for systematic review and network meta-analysis of randomised controlled trials
Pawin Numthavaj, Thunyarat Anothaisintawee, John Attia, et al.
BMJ Open (2024) Vol. 14, Iss. 3, pp. e077916-e077916
Open Access | Times Cited: 1
OnabotulinumtoxinA injection in the treatment of chronic migraine
Yen-Feng Wang
Progress in brain research (2020), pp. 171-206
Closed Access | Times Cited: 9
Switching OnabotulinumtoxinA to Monoclonal Anti-CGRP Antibodies in Drug-Resistant Chronic Migraine
Luigi Francesco Iannone, Davide Fattori, Martina Marangoni, et al.
CNS Drugs (2023) Vol. 37, Iss. 2, pp. 189-202
Closed Access | Times Cited: 3
Efficacy of galcanezumab in patients with migraine who did not benefit from commonly prescribed preventive treatments
Dulanji Kuruppu, Joshua Tobin, Yanhong Dong, et al.
BMC Neurology (2021) Vol. 21, Iss. 1
Open Access | Times Cited: 7
Update in migraine preventive treatment
Tzu‐Hsien Lai, Tzu-Chou Huang
Progress in brain research (2020), pp. 1-27
Closed Access | Times Cited: 6
Galcanezumab for the Prevention of Migraine
Lindsay Frerichs, Deborah I. Friedman
Pain Management (2020) Vol. 11, Iss. 2, pp. 101-112
Closed Access | Times Cited: 5
Advances in pharmacotherapy for the prophylactic treatment of resistant and refractory migraine
Mira Pauline Fitzek, Bianca Raffaelli, Uwe Reuter
Expert Opinion on Pharmacotherapy (2022) Vol. 23, Iss. 10, pp. 1143-1153
Closed Access | Times Cited: 3
Galcanezumab: A Review in the Prevention of Migraine and Treatment of Episodic Cluster Headache
Lesley J. Scott
Drugs (2020) Vol. 80, Iss. 9, pp. 893-904
Closed Access | Times Cited: 2
Combined Prophylaxis of Chronic Migraine with OnabotulinumtoxinA and Anti-CGRP Antibodies
Audrey Blazek
(2023)
Open Access
It is time anti-CGRP monoclonal antibodies be considered first-line prophylaxis for migraine
Gabriel Taricani Kubota
Arquivos de Neuro-Psiquiatria (2022) Vol. 80, Iss. 5 suppl 1, pp. 218-226
Open Access
Page 1

Scroll to top